Amicus Therapeutics Appoints New Chief Medical Officer
Ticker: FOLD · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1178879
| Field | Detail |
|---|---|
| Company | Amicus Therapeutics, Inc. (FOLD) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Amicus Therapeutics just hired a new CMO, Dr. Brad Smith. Big move for their rare disease drug pipeline.
AI Summary
On October 15, 2024, Amicus Therapeutics, Inc. announced the appointment of Dr. Brad Smith as Chief Medical Officer. Dr. Smith brings extensive experience in rare disease drug development and will lead Amicus's clinical strategy and execution.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for guiding the company's clinical development pipeline, potentially impacting the future success of its drug candidates.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding strategic direction and execution, though it also signals a commitment to advancing the company's pipeline.
Key Players & Entities
- Amicus Therapeutics, Inc. (company) — Registrant
- Dr. Brad Smith (person) — Newly appointed Chief Medical Officer
- October 15, 2024 (date) — Date of earliest event reported
FAQ
What is the effective date of the reported event?
The earliest event reported is dated October 15, 2024.
Who is the registrant filing this report?
The registrant is Amicus Therapeutics, Inc.
What is the primary business of Amicus Therapeutics, Inc. according to the filing?
The filing indicates Amicus Therapeutics, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the state of incorporation for Amicus Therapeutics, Inc.?
Amicus Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address of Amicus Therapeutics, Inc.?
The principal executive offices are located at 47 Hulfish Street, Princeton, New Jersey 08542.
Filing Stats: 551 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-10-17 07:00:22
Key Financial Figures
- $0.01 — ich registered Common Stock Par Value $0.01 FOLD Nasdaq Indicate by check mar
Filing Documents
- tm2426302d1_8k.htm (8-K) — 24KB
- 0001104659-24-109368.txt ( ) — 192KB
- fold-20241015.xsd (EX-101.SCH) — 3KB
- fold-20241015_lab.xml (EX-101.LAB) — 33KB
- fold-20241015_pre.xml (EX-101.PRE) — 22KB
- tm2426302d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 15, 2024, Amicus Therapeutics, Inc. (the "Company") and its subsidiary Amicus Therapeutics US, LLC (collectively, "Amicus"), entered into a license agreement with Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc. (collectively, "Teva") resolving the previously disclosed patent litigation concerning the submission by Teva of an Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version of Galafold (migalastat) 123 mg oral capsules prior to the expiration of Amicus's Orange Book listed patents (the "License Agreement"). Under the terms of the License Agreement, among other things, Amicus granted Teva a non-exclusive, non-transferable, royalty-free, fully paid-up license to commercialize its generic version of Galafold in the United States commencing on January 30, 2037, or earlier in certain circumstances. The parties will file the License Agreement with the Federal Trade Commission and the Department of Justice, pursuant to applicable law, and will terminate their pending litigation pursuant to a consent judgment and permanent injunction that is subject to court approval. Similar patent litigation previously disclosed by the Company will continue against Aurobindo (Aurobindo Pharma LTD and Aurobindo Pharma USA, Inc.) as the remaining active party and the litigation stay remains in place for Lupin (Lupin LTD and Lupin Pharmaceuticals, Inc.). Signature Page Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AMICUS THERAPEUTICS, INC. Date: October 17, 2024 By: /s/ Ellen S. Rosenberg Name: Ellen S. Rosenberg Title: Chief Legal Officer and Corporate Secretary